Morepen Laboratories

Morepen Laboratories Limited submitted a status report showing no physical share transfer requests were received, processed, approved, or rejected during September 2025 under a special 6-month window for re-lodgement of physical share transfers. The report was prepared by the company's Registrar and Transfer Agent, MAS Services Limited, and covers the period from September 1 to September 30, 2025. All metrics including number of requests received, processed, approved, rejected, and average processing time were reported as nil or not applicable.

Morepen Medipath has established a 50:50 joint venture partnership with UAE-based Bimedical FZE. The joint venture will focus on manufacturing medical devices.

Morepen Laboratories Limited held its 40th Annual General Meeting on September 6, 2025, via video conferencing, chaired by Sushil Suri, Chairman and Managing Director. The company addressed 11 agenda items including adoption of audited financial statements for the year ended March 31, 2025, and declaration of a final dividend of ₹0.20 per equity share with face value of ₹2 each. Key resolutions included the reappointment of Sanjay Suri as director, ratification of cost auditor remuneration for M/s. Vijender Sharma & Co., and appointment of M/s. PD and Associates as secretarial auditor for five years. Special business items covered the re-appointment of Dr. Savita as Independent Director, Sanjay Suri's re-appointment as Whole-Time Director, and extension of time for transferring the Medical Devices Business to subsidiary Morepen Medipath Limited. The meeting also approved salary arrangements for relatives of key management personnel and conversion of loans into shares or convertible instruments. Electronic voting was conducted with Mr. Praveen Dua appointed as scrutinizer, and the meeting concluded at 2:19 p.m.